Issue 7/2022
Content (20 Articles)
Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy
Chuan Liu, Guangwei Zhang, Kanghui Xiang, Yohan Kim, Roxane R. Lavoie, Fabrice Lucien, Ti Wen
Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice
Xiaoxiao Jin, Xiaotao Liu, Zining Zhou, Yan Ding, Yandan Wu, Jie Qiu, Chuanlai Shen
TGF-β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer
Luciana Gneo, Nagy Rizkalla, Rahul Hejmadi, Francis Mussai, Carmela de Santo, Gary Middleton
Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy
Luya Cai, Xuedan Du, Cheng Zhang, Shanshan Yu, Lixiao Liu, Jinduo Zhao, Ye Zhao, Chunhong Zhang, Jinting Wu, Bin Wang, Yingyu Chen, Xiaoping Su, Xiaojian Yan, Wenfeng Li
Redirecting host preexisting influenza A virus immunity for cancer immunotherapy
Bharat K. R. Chaganty, Songbo Qiu, Yang Lu, Gabriel Lopez-Berestein, Bulent Ozpolat, Zhen Fan
Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study
Xiangling Chu, Huiping Qiang, Mengqing Xie, Xing Li, Jing Zhao, Yan Wu, Juan Zhou, Jinyan Ye, Chao Zhao, Chaonan Han, Tianqing Chu, Chunxia Su
Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis
Jun-shuai Xue, Hui Liu, Guang-Xiao Meng, Zi-Niu Ding, Lun-Jie Yan, Sheng-Yu Yao, Hai-Chao Li, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Tao Li
Distribution, phenotype, functional and clinical relevance of CD8+CD103+ tissue-resident memory T cells in human gastric cancer
Yang Shen, Xiao-long Li, Yu-xian Li, Zhi-guo Shan, Yong-liang Zhao, Ping Cheng, Zhuo Zhao, Jin-yu Zhang, Weisan Chen, Yuan Zhuang, Dai-yuan Ma, Quan-ming Zou, Yuan Qiu, Liu-sheng Peng
Endoplasmic reticulum stress-induced release and binding of calreticulin from human ovarian cancer cells
Trefa M. Abdullah, Jacqueline Whatmore, Edwin Bremer, Rimantas Slibinskas, Marek Michalak, Paul Eggleton
Chemical screening identifies novel small molecule activators of natural killer cell cytotoxicity against cancer cells
Grace Lee, Sheela Karunanithi, Bruce Posner, Hanspeter Niederstrasser, Hong Cheng, Yuriy Federov, Shivaprasad Manjappa, Karam Musaitif, Huaiyu Wang, Zachary Jackson, David Wald
Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy
Qiaoyun Tan, Liyuan Dai, Yanrong Wang, Shuxia Liu, Te Liang, Rongrong Luo, Shasha Wang, Ning Lou, Haizhu Chen, Yu Zhou, Qiaofeng Zhong, Jianliang Yang, Puyuan Xing, Xingsheng Hu, Yutao Liu, Shengyu Zhou, Jiarui Yao, Di Wu, Zhishang Zhang, Le Tang, Xiaobo Yu, Xiaohong Han, Yuankai Shi
The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study
Wenxian Wang, Xiaodong Gu, Liping Wang, Xingxiang Pu, Huijing Feng, Chunwei Xu, Guangyuan Lou, Lan Shao, Yibing Xu, Qian Wang, Siyuan Wang, Wenbin Gao, Yiping Zhang, Zhengbo Song
Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens
Gerulf Hänel, Caroline Angerer, Katja Petry, Felix S. Lichtenegger, Marion Subklewe
Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study
Geoffroy Bilger, Nicolas Girard, Hélène Doubre, Matteo Giaj Levra, Etienne Giroux-Leprieur, Frederique Giraud, Chantal Decroisette, Matthieu Carton, Marie Ange Massiani
Metformin inhibits human non-small cell lung cancer by regulating AMPK–CEBPB–PDL1 signaling pathway
Tao Lu, Ming Li, Mengnan Zhao, Yiwei Huang, Guoshu Bi, Jiaqi Liang, Zhencong Chen, Yuansheng Zheng, Junjie Xi, Zongwu Lin, Cheng Zhan, Wei Jiang, Qun Wang, Lijie Tan
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab
Mathilde Bureau, Thierry Chatellier, Tanguy Perennec, Thomas Goronflot, Charlotte Greilsamer, Anne-Laure Chene, Raafet Affi, Eric Frampas, Jaafar Bennouna, Elvire Pons-Tostivint
Identification of prognostic genes in the pancreatic adenocarcinoma immune microenvironment by integrated bioinformatics analysis
Haolan Wang, Liqing Lu, Xujun Liang, Yongheng Chen
Efficient adoptive transfer of autologous modified B cells: a new humanized platform mouse model for testing B cells reprogramming therapies
Audrey Page, Emilie Laurent, Didier Nègre, Caroline Costa, Véronique Pierre, Thierry Defrance, François-Loïc Cosset, Floriane Fusil
Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11–13 2019, Verona, Italy
Matteo Bellone, Marco Bregni, Vincenzo Bronte, Stefano Ugel, Pier Francesco Ferrucci, Massimo Di Nicola, Paola Nisticò, Gaia Zuccolotto, Antonio Rosato, Vincenzo Russo, Antonio Sica, Mario P. Colombo
Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15–16, 2020
Matteo Bellone, Arianna Brevi, Vincenzo Bronte, Silvia Dusi, Pier Francesco Ferrucci, Paola Nisticò, Antonio Rosato, Vincenzo Russo, Antonio Sica, Gabriele Toietta, Mario Paolo Colombo